FDA Approves Groundbreaking Drug to Slow Alzheimer's Disease
TL;DR
The FDA has granted approval to Leqembi, a drug developed by Japanese drugmaker Eisai and US-based Biogen, making it the first approved treatment that can slow the progression of Alzheimer's. Leqembi works by reducing amyloid plaques in the brain, addressing the underlying biology of the disease. However, it is not a cure and requires professional administration every two weeks. The drug's high cost of $26,500 per year may limit accessibility, with Medicare unlikely to cover it. The number of Americans with Alzheimer's is expected to increase, leading to a greater focus on treatments and diagnostics for the disease.
- The first drug that slows Alzheimer's has finally received FDA approval Engadget
- FDA Approves Promising Drug to Treat Alzheimer's Disease Inside Edition
- New Alzheimer’s treatment could start in Louisville during the coming weeks WAVE 3
- FDA approves new drug for Alzheimer's | GMA Good Morning America
- Biogen’s big Alzheimer’s drug win fails to boost the stock MarketWatch
Want the full story? Read the original reporting
Read on Engadget